164 related articles for article (PubMed ID: 23018213)
1. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells.
Chen A; Qian D; Wang B; Hu M; Lu J; Qi Y; Liu DX
Int J Gynecol Pathol; 2012 Nov; 31(6):532-7. PubMed ID: 23018213
[TBL] [Abstract][Full Text] [Related]
2. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
Monaco SE; Angelastro JM; Szabolcs M; Greene LA
Int J Cancer; 2007 May; 120(9):1883-90. PubMed ID: 17266024
[TBL] [Abstract][Full Text] [Related]
3. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.
Hu M; Wang B; Qian D; Li L; Zhang L; Song X; Liu DX
Anticancer Res; 2012 Oct; 32(10):4385-94. PubMed ID: 23060563
[TBL] [Abstract][Full Text] [Related]
4. [MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro].
Tang R; Cui ZM; Lou YH
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):846-50. PubMed ID: 23302126
[TBL] [Abstract][Full Text] [Related]
5. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors.
Wehrli BM; Krajewski S; Gascoyne RD; Reed JC; Gilks CB
Int J Gynecol Pathol; 1998 Jul; 17(3):255-60. PubMed ID: 9656122
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.
Dluzen D; Li G; Tacelosky D; Moreau M; Liu DX
J Biol Chem; 2011 Mar; 286(9):7705-13. PubMed ID: 21212266
[TBL] [Abstract][Full Text] [Related]
8. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ
Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219
[TBL] [Abstract][Full Text] [Related]
9. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Zhou S; Tang L; Wang H; Dai J; Zhang J; Shen L; Ng SW; Berkowitz RS
Gynecol Oncol; 2013 Oct; 131(1):69-76. PubMed ID: 23820113
[TBL] [Abstract][Full Text] [Related]
12. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
13. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
14. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
15. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Sheng Z; Li L; Zhu LJ; Smith TW; Demers A; Ross AH; Moser RP; Green MR
Nat Med; 2010 Jun; 16(6):671-7. PubMed ID: 20495567
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.
Corr BR; Finlay-Schultz J; Rosen RB; Qamar L; Post MD; Behbakht K; Spillman MA; Sartorius CA
Int J Gynecol Cancer; 2015 Nov; 25(9):1565-73. PubMed ID: 26495758
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
18. The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.
Shen DF; Liu X; Yang XF; Fang L; Gao Y; Zhao S; Wu JC; Shi S; Li JJ; Zhao XX; Gou WF; Zheng HC
Tumour Biol; 2016 Mar; 37(3):2909-24. PubMed ID: 26409451
[TBL] [Abstract][Full Text] [Related]
19. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
[TBL] [Abstract][Full Text] [Related]
20. LncSOX4 serves an oncogenic role in the tumorigenesis of epithelial ovarian cancer by promoting cell proliferation and inhibiting apoptosis.
Liu Y; Wang Y; Yao D; Cui D
Mol Med Rep; 2018 Jun; 17(6):8282-8288. PubMed ID: 29693704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
